Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC13A5 | Q86YT5 | 3/20 | 0.50 |
| ▸ | SLC13A2 | Q13183 | 1/20 | 0.50 |
| ▸ | SLC13A3 | Q8WWT9 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.36 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.35 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.35 |
| ▸ | CSF1R | P07333 | 1/20 | 0.33 |
| ▸ | KIT | P10721 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | CCR1 | P32246 | 1/20 | 0.32 |
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
| ▸ | CCR8 | P51685 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12093547 | 0.82 | SLC13A5 (0.51) | SLC13A5SLC13A2SLC13A3CYP3A4CYP2C9 | |
| SCHEMBL24092341 | 0.81 | SLC13A5 (0.47) | SLC13A5SLC13A2SLC13A3CYP3A4CYP2C9 | |
| SCHEMBL20670339 | 0.81 | SLC13A5 (0.47) | SLC13A5SLC13A2SLC13A3CYP3A4CYP2C9 | |
| SCHEMBL1477059 | 0.81 | CYP2C9 (0.43) | SLC13A5SLC13A2SLC13A3CYP2C9ALDH1A1 | |
| SCHEMBL5780868 | 0.81 | SLC13A5 (0.50) | SLC13A5SLC13A2SLC13A3CYP3A4CYP2C9 | |
| SCHEMBL5779592 | 0.79 | CNR2 (0.36) | SLC13A5SLC13A2SLC13A3ALDH1A1GFER | |
| SCHEMBL22690068 | 0.79 | CYP2C9 (0.42) | SLC13A5SLC13A2SLC13A3CYP3A4CYP2C9 | |
| SCHEMBL12250796 | 0.78 | SLC13A5 (0.45) | SLC13A5SLC13A2SLC13A3CYP3A4CYP2C9 | |
| SCHEMBL24802484 | 0.77 | SLC13A5 (0.44) | SLC13A5SLC13A2SLC13A3CYP3A4CYP2C9 | |
| SCHEMBL24802482 | 0.75 | SLC13A5 (0.49) | SLC13A5SLC13A2SLC13A3CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023111181-A1 | SMALL MOLECULE MODULATORS OF IL-17 | LEO PHARMA A/S (DK) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023111181-A1 | SMALL MOLECULE MODULATORS OF IL-17 | LEO PHARMA A/S (DK) | 2023-06-22 | — | — | WO | disclosed |
| EP-1254904-B1 | NOVEL PIPERIDINE COMPOUNDS AND DRUGS CONTAINING THE SAME | EISAI CO LTD (JP) | 2006-05-24 | — | — | EP | disclosed |
| US-6784192-B2 | NA+ CHANNEL INHIBITORY ACTION IS USEFUL FOR THERAPY AND PREVENTION FOR EXAMPLE, ARRHYTHMIA, VARIOUS NEURALGIAS AND ANALGESIC | EISAI CO., LTD. (JP) | 2004-08-31 | — | — | US | disclosed |
| US-20030220368-A1 | Novel piperidine compouds and drugs containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-11-27 | — | — | US | disclosed |
| EP-1254904-A1 | NOVEL PIPERIDINE COMPOUNDS AND DRUGS CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2002-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220368-A1 | Novel piperidine compouds and drugs containing the same | TRPV1, CACNA1D, KCND2 | SLC13A5 202/4885SLC13A2 650/4885SLC13A3 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.